Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients
Open Access
- 15 July 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 946692
Abstract
Glioma is the most common primary brain tumor in the human brain. The present study was designed to explore the expression of PIMREG in glioma and its relevance to the clinicopathological features and prognosis of glioma patients. The correlations of PIMREG with the infiltrating levels of immune cells and its relevance to the response to immunotherapy were also investigated. PIMREG expression in glioma was analyzed based on the GEO, TCGA, and HPA databases. Kaplan–Meier survival analysis was used to examine the predictive value of PIMREG for the prognosis of patients with glioma. The correlation between the infiltrating levels of immune cells in glioma and PIMREG was analyzed using the CIBERSORT algorithm and TIMRE database. The correlation between PIMREG and immune checkpoints and its correlation with the patients’ responses to immunotherapy were analyzed using R software and the GEPIA dataset. Cell experiments were conducted to verify the action of PIMREG in glioma cell migration and invasion. We found that PIMREG expression was upregulated in gliomas and positively associated with WHO grade. High PIMREG expression was correlated with poor prognosis of LGG, prognosis of all WHO grade gliomas, and prognosis of recurrent gliomas. PIMREG was related to the infiltration of several immune cell types, such as M1 and M2 macrophages, monocytes and CD8+ T cells. Moreover, PIMREG was correlated with immune checkpoints in glioma and correlated with patients’ responses to immunotherapy. KEGG pathway enrichment and GO functional analysis illustrated that PIMREG was related to multiple tumor- and immune-related pathways. In conclusion, PIMREG overexpression in gliomas is associated with poor prognosis of patients with glioma and is related to immune cell infiltrates and the responses to immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (81870939)
- Fundamental Research Funds for the Central Universities (2042022kf1216)
- Natural Science Foundation of Hubei Province (2016CFB405)
This publication has 35 references indexed in Scilit:
- Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesFrontiers in Oncology, 2015
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic CellsCancer Immunology Research, 2015
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Targeting Tregs in Malignant Brain Cancer: Overcoming IDOFrontiers in Immunology, 2013
- Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM PatientsPLOS ONE, 2012
- Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-βClinical Cancer Research, 2011
- Glioblastoma-Derived Mechanisms of Systemic ImmunosuppressionNeurosurgery Clinics of North America, 2010
- The CALM and CALM/AF10 interactor CATS is a marker for proliferationMolecular Oncology, 2008
- Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human GliomasClinical Cancer Research, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007